Skip to Main Content

Deepak Cyril Dsouza, MBBS, MD

Professor of Psychiatry; Director Schizophrenia Neuropharmacology Research Group at Yale (SNRGY); Director, Neurobiological Studies Unit, VACHS; Director, VA-CMHC Schizophrenia Research Clinic

Contact Information

Deepak Cyril Dsouza, MBBS, MD

Mailing Address

  • Psychiatry

    950 Campbell Avenue

    West Haven, CT 06516

    United States

Research Summary

Our group has been studying the treatment and pathophysiology of schizophrenia. Our work involves the use of various psychopharmacological probes (ketamine, delta-9-THC, iomazenil, etc) to evaluate the contributions of various neurotransmitter systems (NMDA, cannabinoid, GABA, etc) to the pathophysiology of schizophrenia; laboratory studies of comorbid substance abuse in schizophrenia, (alcohol, cannabis and nicotine) and clinical trials with novel agents for schizophrenia.

Extensive Research Description

    • Neurobiology of Cannabis
    • Cannabinoids, Neural Synchrony and Information Processing
    • Cannabinoid Receptor Function in Alcoholism: Effects of D-9-THC
    • Imaging Nicotinic Acetylcholine Receptors in Schizophrenia
    • GABA Deficits and Vulnerability to Cannabinoid-Induced Psychosis
    • GABA Deficits and Vulnerability to Amphetamine-Induced Psychosis
    • Ketamine Nicotine Interactions in Humans
    • Ketamine Interactions with GLYT1 inhibitor in Humans
    • Cognitive Remediation in the Schizophrenia Trials Network
    • Varenicline for Smoking Cessation in Schizophrenia
  • Coauthors

    Research Interests

    Behavior and Behavior Mechanisms; Mental Disorders; Behavioral Disciplines and Activities; Psychological Phenomena; Psychiatry and Psychology

    Selected Publications

    Clinical Trials

    ConditionsStudy Title
    HeadachesRepeat Dosing of Psilocybin in Migraine Headache
    Diseases of the Nervous System; Mental Health & Behavioral Research; Pain ControlEffects of Psilocybin in Concussion Headache
    Mental Health & Behavioral ResearchFAAH Availability in Psychiatric Disorders: A PET Study
    Mental Health & Behavioral ResearchA Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
    Mental Health & Behavioral ResearchA Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) (TALLY)
    Diseases of the Nervous System; Mental Health & Behavioral ResearchTeen Brain and Behavior Study
    Addictive Behaviors; Child Development & Autism; Mental Health & Behavioral ResearchA longitudinal study of the effects of cannabis exposure on neuro-development in adolescents and young adults
    Mental Health & Behavioral ResearchBXCL501 for Agitation in Schizophrenia (DEX)
    Addictive Behaviors; Mental Health & Behavioral ResearchFatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) (FAAH-I MULTI)
    Mental Health & Behavioral ResearchPredictive Coding and Unusual Experiences
    Diseases of the Nervous System; Mental Health & Behavioral ResearchExamination of Glutamate and mGluR5 in Psychiatric Disorders
    Mental Health & Behavioral ResearchSleep Dependent Learning in Schizophrenia and Psychosis Risk Syndrome
    Diseases of the Nervous System; Mental Health & Behavioral ResearchC4 Gene Dose Effects using 11C-UCB-J PET
    Mental Health & Behavioral ResearchImaging mGluR5 and synaptic density in psychiatric disorders
    Mental Health & Behavioral ResearchImaging SV2A in mood disorders
    Addictive Behaviors; Diseases of the Nervous System; Genetics - Adult; Mental Health & Behavioral ResearchImaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning